# An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

> **NCT00811564** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 148 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
- **DRUG:** latanoprost 0.005%

## Key facts

- **NCT ID:** NCT00811564
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2011-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811564, "An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00811564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*